secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2024-04-23T23:59:59+00:00
Accession:  0001104659-24-050307
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics reports positive Phase 1 data for VCN-01 in pediatric retinoblastoma and exclusive license from SJD
--------------------------------------------------------------------------------

- Phase 1 trial of intravitreal VCN-01 in 9 evaluable patients with refractory retinoblastoma determined positive by Monitoring Committee.
- Safety: no dose-limiting toxicities; most adverse events Grade 1 or 2; no Grade 3+ ocular or systemic toxicities.
- Antitumor activity: 4 patients had unequivocal improvement in vitreous seed density; eye enucleation avoided in 3 patients (1 retained eye after 4 years).
- Theriva will receive exclusive worldwide license and related patents from Sant Joan de Déu-Barcelona Children's Hospital for advanced retinoblastoma treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465924050307/0001104659-24-050307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465924050307/tm2412300d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-050307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer